-
Mashup Score: 3No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis - 7 month(s) ago
Background and Objectives Some patients with multiple sclerosis (MS) receiving ocrelizumab (OCR) report worsening symptoms toward the end of the 6-month infusion cycle (‘wearing off’). The objective of our study was to comprehensively assess changes in symptom burden across 2 consecutive OCR infusion cycles. Methods SYMptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS; [NCT04855617][1]) was an investigator-initiated, 2-center study of patients with MS starting or receiving OCR. Patients’ symptoms were assessed with NeuroQoL short forms, SymptoMScreen, and Work Productivity and Activity Impairment Questionnaire at the start-cycle, mid-cycle, and end-cycle time points in each of the 2 infusion cycles. Symptom scores at the 3 time points within each cycle were compared with repeated-measures ANOVA or the Friedman rank-sum test for non-normal variables. The proportions of patients with a meaningful symptomatic change from the start to the end of each infusion cycle were calculated,
Source: cp.neurology.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0New Consensus Statements on Smoldering Disease in Multiple Sclerosis Developed - Practical Neurology - 7 month(s) ago
An international panel has developed consensus-driven statements on smoldering disease (SD) in multiple sclerosis (MS), including domains such as defi
Source: practicalneurology.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0
Did you know what the inherent variability of all biologics and what degree of variation are acceptable by regulatory bodies?
Source: www.medscape.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0Greater income, education before diagnosis tied to less severe MS... - 7 month(s) ago
Income and education levels before a multiple sclerosis diagnosis were identified in a new study as risk factors for MS symptom severity.
Source: multiplesclerosisnewstoday.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1High-Efficacy Multiple Sclerosis Therapy and Pregnancy - 7 month(s) ago
Natalizumab has been associated with return and rebound of multiple sclerosis (MS) disease activity during pregnancy, in part due to its relatively
Source: www.jwatch.orgCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0HOME - Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors - 7 month(s) ago
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the…
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Are We Ready for Biosimilars in Multiple Sclerosis? Experts Discuss Lessons From Other Immune-Mediated Diseases - 7 month(s) ago
What is the clinical use of biosimilars and how to best communicate with patients to avoid the nocebo effect?
Source: www.medscape.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 1
Did you know what the inherent variability of all biologics and what degree of variation are acceptable by regulatory bodies?
Source: www.medscape.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 3Evolving Concepts in Multiple Sclerosis Clinical Trial Endpoints: What's the Relevance for My Patients? - 7 month(s) ago
Did you know that the primary outcome alone may not be enough to indicate efficacy of a treatment for multiple sclerosis (MS)?
Source: www.medscape.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 1Emotional Issues Could Be Early Sign of MS - 7 month(s) ago
WEDNESDAY, Sept. 27, 2023 (HealthDay News) — A newer understanding of multiple sclerosis (MS) suggests that psychiatric conditions like anxiety and depression may emerge long before classic MS symptoms.“For a long time, it was thought that MS only really began clinically when a person experienced t…
Source: consumer.healthday.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
Free to Read: No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis https://t.co/qQSEy5zPir #NeuroTwitter #MS https://t.co/YRBCqOn7cp